LIXT•benzinga•
LIXTE Biotechnology Announces Pre-Clinical Data Published In BioXriv And International Journal Of Pharmaceutics Confirming LB-100's Conversion To Active Form Endothall, An Effective Cancer Treatment In Combination With Immunotherapy; Potential Biomarker I
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 10, 2025 by benzinga